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PROGNOSTIC IMPLICATIONS OF PATIENTS WITH MAMMOGRAPHICALLY 
OCCULT, EARLY STAGE BREAST CANCER 
Tzu-I Jonathan Yang and Meena S. Moran 
Department of Therapeutic Radiology, Yale University School of Medicine, New Haven, CT. 
 
Purpose: To compare mammographically occult (MamOcc) and mammographically 
positive (MamPos) early-stage breast cancer patients treated with breast-conservation 
therapy (BCT), to analyze differences between the two cohorts. 
Methods: The 2 cohorts were comprised of 214 MamOcc and 2168 MamPos patients 
treated with BCT. Chart reviews were conducted to assess mammogram reports and 
method of detection. All clinical–pathologic and outcome parameters were analyzed to 
detect differences between the two cohorts. 
Results: Median follow-up was 7 years. There were no differences in final margins, T 
stage, nodal status, estrogen/progesterone receptor status, or “triple-negative” status. 
Significant differences included age at diagnosis (p < 0.0001), more positive family 
history (p = 0.0033), less HER-2+ disease (p = 0.0294), and 1° histology (p < 0.0001). At 
10 years, the differences in overall survival, cause-specific survival, and distant relapse 
between the two groups did not differ significantly. The MamOcc cohort had more breast 
relapses (15% vs. 8%; p = 0.0357), but on multivariate analysis this difference was not 
significant (hazard ratio 1.0, 95% confidence interval 0.993–1.007, p = 0.9296). Breast 
relapses were more commonly not picked up on mammography in the MamOcc cohort 
(32% 12% p = 0.0136).  
Conclusions: Our study suggests that there are clinical–pathologic variations for the 
MamOcc cohort vs. MamPos patients that may potentially affect management, but that 
breast relapse rates after BCT are ultimately not significantly different for these 2 
cohorts. Breast recurrences were more often mammographically occult in the MamOcc 
cohort; consideration should be given to closer follow-up and alternative imaging 
strategies (ultrasound, breast MRI) for routine post-treatment examination. To our 
knowledge, this represents the largest series addressing the prognostic significance of 
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For early-stage breast cancer, mammography is an integral part of the workup 
before definitive treatment.  Although diagnostic mammography is the standard breast 
imaging method used preoperatively to verify the location and extent of disease and to 
determine whether a patient is eligible for breast-conservation therapy (BCT), 9–26% of 
patients with breast cancer present with false-negative mammograms (1-4) at the time of 
diagnosis.  A list of previous studies examining the rate of false-negative mammogram in 
women with breast cancer is provided in Table 1. Whether the cause of the negative 
result is dense breast tissue, diffuse disease, poor quality of the mammogram, or 
oversight of the primary tumor, the prognostic implications of a false-negative 
mammogram at presentation are generally unknown.    
 
Table 1: Prevalence of mammographically occult breast cancer in literature. 
 




Cancer Patients (n) 
Percentage of 
Mammographically 
Occult Brest Cancer 
Patients (%) 
 
Wallis et al. (1) 75 871 9 
 
Feig et al. (2) 138 20 14 
 
Edeiken et al. (3) 108 499 22 
 
Niloff et al. (4) 160 41 26 
 
Samuels et al. (5) 55 542 10 
 
Morrow et al. (6) 52 269 19 
 





This thesis provides a summary of current common breast cancer screening 
imaging modalities, the clinical benefit of mammography, and predictive values of 
abnormalities on mammogram.  It also provides an introduction to the concept of 
mammographic sensitivity, mammographically occult breast cancer, and the utilization of 
breast conservation therapy (BCT).   Lastly, it details our investigation on the clinical and 
pathologic features and long-term outcome of patients with mammographically occult 
breast cancer.   
 
Screening for Breast Cancer 
Approximately 207,090 women in the United States are diagnosed with invasive 
breast cancer annually (8), with the majority of the breast cancers diagnosed as a result of 
an abnormal screening study.  A variety of imaging modalities have been used for 
detection of breast cancer.  Although Mammography has been and remains the primary 
imaging modality for the screening of breast cancer in the United States, a percentage of 
cancers are not visible mammographically, and it has a lower sensitivity for cancer 
detection in dense breast tissues (9).  Furthermore, mammographic sensitivity seems to 
decrease and is insufficient for early diagnosis of breast cancer in women who are at 
increased familial risk with or without documented BRCA mutation (10).  These issues 
have led to ongoing investigations for alternate imaging modalities in screening for breast 
cancer in specific patient populations, such as younger women with dense breast, or 
women with strong familial history of breast cancer.  
Ultrasound is primarily used for diagnostic follow-up and further clarification of a 
questionable lesion and for visual guidance during a needle biopsy.  Furthermore, it is 
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considered the first line imaging modality for breast imaging in pregnant women or in 
women less than 30 years of age with focal breast symptoms. A large, multi-center 
prospective study by Berg et al. evaluated the effectiveness of breast cancer screening 
using ultrasound in addition to mammography in elevated risk women with 
heterogeneously dense breast tissue in at least one quadrant.  The authors found that of 
the 41 patients who were diagnosed with cancer, 8 demonstrated lesions on both 
ultrasound and mammography, 12 were detected by lesions on ultrasound alone, and 12 
by mammography alone.  The authors concluded that adding a screening ultrasound to 
mammography would lead to an additional 1.1-7.2 cancers per 1000 women (11).  
Interestingly, in addition to the 29% of the tumors which were mammographically occult, 
an additional 20% of participants diagnosed of cancer (8 patients) demonstrated no 
abnormality on either the mammogram or ultrasound.   
Magnetic resonance imaging (MRI) is an emerging imaging modality for the 
screening of breast cancer that is under investigation.  Currently MRI, in addition to 
mammography, is more commonly utilized among patients who are at high-risk for 
developing breast cancer.  MRI relies on the increased vascularity of neoplasms and has 
been found to have higher sensitivity in detecting breast cancer when compared to 
mammography. The sensitivity has been demonstrated to be less dependent on breast 
density (12).  This makes MRI an attractive screening tool for women with an elevated 
risk of developing breast cancer.  In 2008, Warner and colleagues published their 
findings of a systemic review on studies after 1994 examining the use of MRI and 
mammography for screening of women at very high risk for breast cancer (13).  From the 
11 prospective studies included in their review, the authors found the sensitivity of 
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mammography varied from 14-59% when a positive mammogram was defined as a 
Breast Imaging Reporting and Data System (BI-RADS) 4 or 5 score, while the sensitivity 
of MRI ranged from 51-100%.   The downside of using MRI routinely to screen all 
patients is the lower specificity and higher false positive rate, often warranting additional 
work-up (i.e. biopsies).  A recent study by Riedl et al. compared mammography, 
ultrasound, and MRI of the breast used for the surveillance of women at high risk for 
breast cancer concluded specificities of 98%, 98%, and 92% for mammography, 
ultrasound and MRI, respectively.  This study also documented the higher false positive 
rate of MRI compared to mammography and ultrasound (81% vs. 64%, 68%, 
respectively) (14).  
 
Origin and the Clinical Benefit of Mammography 
 The first x-ray of the breast tissue was obtained in 1913 by Dr. Albert Salomon, a 
surgeon who reported the use of radiography of mastectomy specimens that demonstrated 
the primary tumors as well as spread to axillary lymph node (15).   In 1949, Dr. Raul 
Leborgne was the first to report the significant association of radiographically detectable 
microcalcifications and breast carcinoma, reported finding radiographically visible 
microcalcifications in 30% of patients with breast cancer and thus setting the stage for 
screening mammography.  In 1960, Dr. Robert L. Egan described a kilovoltage 
mammographic technique that was easily reproducible, which led to the development and 
widespread use of mammography.  In 1963, the Cancer Control Program of the U.S. 
Public Health Service sponsored a conference at the M.D. Anderson Hospital, reporting 
on the usefulness and reproducibility of mammography (15).  The results of a 24 
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institutions nationwide mammography study were presented at the conference: the true-
positive rate for mammography was 79%, and the false-negative rate was 21% (16).  The 
results of this study established that other radiologists could learn the technique of 
mammography developed by Dr. Robert Egan, that mammography could enable 
differentiation between benign and malignant lesions, and that mammography could be 
used to screen for cancer in asymptomatic women.  Interestingly, despite the more recent 
advancements in mammographic techniques, the false-negative rate of mammography 
appears to be relatively consistent through the years (see Table 1), indicating the 
continuing need for patient selection and investigations of emerging imaging modality in 
breast cancer screening.  
 Mammography became the standard for breast cancer screening in the 1970s.  In 
1973, Strax and colleagues published their results of a randomized mass screening 
program using mammography as well as clinical examination in a group of 62,000 
women aged 40 to 60.  The authors found that mammography contributed substantially to 
the detection of breast cancer.  Of 132 breast cancers detected through screening, 44 
(33%) were found on mammography only and would have been missed if it were 
omitted.   At 7-year follow-up, a 33% reduction in mortality rate was attributed to the use 
of mammography (17).  In a 2002 Lancet publication, Nyström and colleagues 
demonstrated the advantageous effect of breast screening using mammography on breast 
cancer mortality after long-term follow-up (15.8 years) of the Swedish randomized 
controlled trials.  The authors showed a 21% reduction in breast cancer mortality when 
comparing women who underwent mammography screening (164,770 patients) to those 
who did not (1,688,440 patients).  They demonstrated that the benefit in terms of 
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cumulative breast cancer mortality reduction started to emerge at 4 years after 
randomization and continued to increase to approximately 10 years.  Thereafter, the 
benefit in absolute reduction was maintained throughout the period of observation (18). 
In a recent Cochrane Database Systemic Review article, Gøtzsche et al. published their 
assessment of randomized trials comparing mammographic screening with no 
mammographic screening to determine the effect of screening for breast cancer with 
mammography on mortality and morbidity.  The authors identified seven eligible trials 
and included 600,000 women in the analyses and concluded that mammographic 
screening is likely to reduce breast cancer mortality with an estimate 15%-20% reduction 
corresponding to an absolute risk reduction of 0.05% (19).   From these studies, it is 
reasonable to conclude that the implementation of mammography has proven beneficial 
in reducing breast cancer related death worldwide.   
 Recently, there has been a great deal of controversy regarding changes in breast 
cancer screening recommendations released by the US Preventive Services Task Force 
(USPSTF) in 2009, and one of the recommendations made by the Task Force was to 
delay in the initial mammographic screening of asymptomatic women from age 40 to age 
50 (20).   Although the analysis of the Task Force included eight randomized trials and 
demonstrated an estimate relative risk for breast cancer-associated mortality of 0.85 (95% 
CI, 0.75-0.96), or 15% average breast cancer mortality reduction, for women of 39-49 
years of age who undergo screening mammography, the Task Force also found that 
nearly 1 in 10 women in their 40s had a false-positive result per round of screening.   
Eighty percent of the false-positive screening resulted in additional imaging, and 10% of 
women with false-positive screenings resulted in biopsy (21).  The USPSTF analysis 
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recognized the benefits of routine mammography starting at age 40, but the farms in 
terms of false-positive results are real as well.  Clearly, there is a need of investigations 
that can help us better delineate the best imaging modalities in breast cancer screening for 
women younger than age 50.   
 
Abnormalities on Mammogram 
When mammographic findings that may be associated with breast cancer are 
identified at screening, further diagnostic work-up is required.  These abnormal findings 
often include masses, calcifications, architectural distortion, and asymmetry.  The 
accuracy of mammography is directly related to the positive predictive values of the 
findings.  A large analysis of the positive predictive value associated with specific 
mammographic findings in screening and diagnostic examinations using the San 
Francisco Mammography Registry was published by Venkatesan and colleagues in 2009 
(22).  The study included 10,641 mammograms performed in 20 facilities between 1998 
and 2002.  The purpose of the study was to evaluate the risk of cancer associated with 
specific abnormal findings in mammographic examinations, to determine the distribution 
and prevalence of these findings, and to analyze positive predictive value variation 
according to user and patient factors.  The authors found that masses and calcifications 
were the most commonly recording findings.  While masses were much more prevalent 
(69%) in diagnostic examination, in screening examinations masses, calcifications, and 
asymmetry were equally common.  Architectural distortion was an uncommon finding for 
both screening and diagnostic mammograms.  The positive predictive values of specific 
mammographic findings are listed in Table 2.  The authors concluded that overall, one in 
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twenty invasive cancers was identified with asymmetry, one in sixteen invasive cancers 
was identified with architectural distortion, one in five invasive cancer was identified 
with calcification, and two in three invasive cancers were identified with a mass. 
 
Table 2:  Prevalence and positive predictive value of mammographic abnormalities 










1417 1345 265 998 
Prevalence (%) 
 















4534 1741 108 233 
Prevalence (%) 
 





19.6 24.1 60.2 14.6 
 
Mammographic Sensitivity 
Although mammography remains the primary imaging modality for breast cancer 
screening, it remains limited in its ability to detect all cancers; its sensitivity ranges from 
60-98% and has been reported to be as low as 30% in women with dense breasts (23-26).   
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In 1996, Kerlikowske and colleagues published a large cross-sectional study on 
mammography and the effects of patient’s age and breast density on its sensitivity(25).  
The study, with over 20,000 women aged 30 years and older who underwent 
mammographic screening from 1985 to 1992, had 238 women who were subsequently 
diagnosed with breast cancer.  The authors found that the sensitivity of screening 
mammography was the highest for women ages 50 or older with primarily fatty breasts 
compared to dense breasts (98.4% vs. 83.7%).  For women less than 50 years of age, the 
study suggested that breast density did not seem to affect the sensitivity of 
mammography (81.8% for women with primarily fatty breast, 85.4% for women with 
dense breast).  When the patients were further stratified by age, mammographic 
sensitivity was lower in women of younger age (see Table 3).   
 
Table 3: Sensitivity of screening mammography of all breast cancer (25). 








22 45 47 51 34 
Sensitivity (%) 77.3 86.7 83.6 94.1 91.2 
 
The authors concluded that the lower sensitivity of mammography in younger 
women was due primarily to the more aggressive tumors in younger women, and was not 
due to denser breast tissue as the sensitivity of screening mammography decreased with 
increasing size of tumor, and a lower sensitivity for detecting large tumors is more 
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pronounced in younger than in older women. But contradicting these results, other studies 
have suggested that breast density is, in fact, a significant predictor of mammographic 
detections (26, 27).  In Kolb and colleagues’ investigation comparing screening 
mammography, physical examination, and breast ultrasound, the authors found that 
mammographic sensitivity declined significantly with increasing density and in younger 
women with dense breast, and these effects were independent.  The sensitivity of 
mammography for women 49 years or younger and 50 years or older were 58% and 83%, 
respectively. The sensitivity of mammography for women with breast density decreased 
from densities less than 25% having 98% sensitivity, versus 25-50% breast density with 
83% sensitivity; 51-75% breast density with 64% sensitivity, and more than 75% breast 
density with 48% sensitivity (27).   
More recently, Ernster et al. analyzed 653,833 mammograms of 540,738 women 
between 40 and 84 years of age screened between 1996 and 1997 from the 
mammography registries of the Breast Cancer Surveillance Consortium (28).   The 
purpose of their study was to determine mammography’s role and ability in the screening 
and detection of ductal carcinoma in situ (DCIS), a non-invasive form of breast cancer.   
While doing so, the authors also provided findings for invasive breast cancer.  They 
determined that the sensitivity of screening mammography for all patients was higher for 
DCIS than it was for invasive breast cancer (86% vs. 75%, respectively). Table 4 details 
the percentages of positive screen stratified by patients’ age in their investigation.    The 
authors concluded that approximately 1 in every 1300 screening mammograms leads to a 
diagnosis of DCIS.  The increased sensitivity in detecting DCIS when compared to 
invasive breast cancer could be attributed to the microcalcifications associate with DCIS. 
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In dense or heterogeneously dense breast tissue, microcalcifications are easier to detect 
on mammograms and the DCIS may never become clinically apparent, thus potentially 
biasing the sensitivity for detecting DCIS upward.  
 
Table 4: Mammographic sensitivity in detecting DCIS and invasive cancer (28).  




211551 200255 135376 106651 
DCIS 
      Cases Diagnosed (n) 
 
134 155 165 137 
DCIS 
      Sensitivity (%) 
 
88 88 84 83 
Invasive Cancer 
      Cases diagnosed (N) 
450 792 709 724 
Invasive Cancer 
      Sensitivity (%) 
67 72 76 83 
 
 From the above studies, it is reasonable to conclude that mammography is 
effective in screening for both DCIS and invasive breast cancer, however, its sensitivity 
for the detection of invasive cancer correlates positively with patient’s age and negatively 
with breast density.    Breast density itself is a major independent risk factor for breast 
cancer that cannot be explained by the masking of cancers by dense breast tissue (29), 
and previous studies suggested that younger patients who presented with false negative 
mammograms could represent a more aggressive form of cancer (25, 30). Therefore it is 
necessary to understand the pathology of mammographically occult breast cancer and to 
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evaluate its prognostic indication and to determine the most suitable treatment for 
patients diagnosed with mammographically occult tumors.   
 
Other Factors Associated with Mammographically Occult Breast Cancer  
 Although false negative mammogram is often attributed to dense breast 
parenchyma in younger patients, inadequate radiographic technique, observer error, and 
diffuse tumor histology have also been suggested (1, 31, 32).  In an early study by 
Holland et al., the authors suggested that tumors of diffuse invasive type with poorly 
outlined mass, such as invasive lobular carcinomas with poor desmoplastic reaction, may 
lead to false negative mammograms, even in an advanced stage (33).  This same finding 
of diffuse histology leading to a highly risk of false negative mammographic screening 
was also reported by Hollingsworth et al. (32).  Morrow and colleagues in 1997 showed 
that particular histological tumor types, such as tubular carcinoma (13.5% of 
mammographically occult tumors and 1.8% of mammographically evident tumors), are 
more often associated with mammographically occult breast carcinoma (6).  In another 
investigation, Wallis et al. noted that 5.5% of mammographically occult carcinomas had 
medullary histology compared with 0.8% of their mammographically evident cohort (1).   
 
Breast Conservation Therapy 
 To be able to evaluate the appropriate treatment for patients diagnosed with early 
stage mammographically occult breast carcinoma, the current standard of care for early 
stage breast cancer patients must be understood.  Surgery today remains an integral part 
of early stage breast cancer management.   As an alternative to mastectomy, breast-
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conserving therapy (BCT) has been found to be the therapeutic equivalent of total 
mastectomy in early breast cancer patients through many randomized trials (34-39). In 
BCT, the tumor is first removed with a margin of normal tissue, followed by whole breast 
irradiation (WBI).  Radiotherapy (RT) has been proven to be effective in improving local 
control and long-term survival (40-45).  Several key randomized studies are shown in 
Table 5.  In 2002, Fisher and colleagues published their twenty-year follow up of the 
National Surgical Adjuvant Breast and Bowel Project (NSABP) B-04 randomized trial 
comparing total mastectomy, wide local resection, and wide local resection plus breast 
radiation (36).  Between 1976 and 1986, a total of 2163 patients with stage I or II breast 
carcinoma were assigned to one of the three arms: mastectomy, lumpectomy, or 
lumpectomy plus 50 Gy of radiation to the whole breast.   The authors at twenty-year 
follow up concluded that lumpectomy followed by breast irradiation continues to be an 
appropriate treatment for women with early stage breast cancer.  Some of the significant 
findings of the recent publication included a significantly higher ipsilateral breast 
recurrence rate for women who underwent lumpectomy and without WBI (39.2% vs. 
14.3% in women who underwent lumpectomy and breast irradiation), demonstrating the 
benefit of local control with radiotherapy to the intact breast.  There were no significant 
differences in disease-free survival, distant-disease-free survival, or overall survival 
amongst the three groups of women.  The hazard ratio for death among the women who 
underwent lumpectomy followed by breast irradiation as compared to mastectomy was 






















Veronesi et al. (39) 567 10 5.83 23.5 
 
Liljegren et al. (46) 381 10 8.5 23 
 
Fisher et al. (36) 930 20 14.3 39.2 
 
 
More recently, the addition of a boost to the tumor bed was found to further 
decrease local recurrence rate (47, 48).   Bartelink and colleagues published their ten-year 
follow up of the randomized boost versus no boost European Organisation for Research 
and Treatment of Cancer (EORTC) 22881-10882 trial in 2007 (49).  The study included 
5318 patients who underwent lumpectomy followed by WBI to 50 Gy and were 
randomly assigned to receive either a boost of 16 Gy or no boost.  At 10 years, the 
incidence of local recurrence for the patients who did not receive boost irradiation was 
10.2%, and for the patients who received boost irradiation it was 6.2%.  Subsequent sub-
set analysis revealed that while the absolute risk reduction was the greatest in young 
women (<40 years of age) and high-grade tumors, a statistically significant benefit existed 
in all patients.  Furthermore, the number of salvage mastectomies was reduced by 41% 























Bartelink et al.  (49) 
 
2661 16 10 6.2 10.2 
Romestaing et al. (48) 
 
521 10 5 3.6 4.5 
 
From these investigations, breast conservation therapy has become a standard 
alternative to mastectomy in patients with early stage breast cancer.  Contraindications to 
a breast conserving approach include: persistent positive resection margins, multicentric 
disease defined as two or more tumors in separate breast quadrants, diffuse malignant–
appearing microcalcifications, history of prior radiation therapy to a field that includes 
the affected breast, or pregnancy. It is important to note that there is no consensus on 
whether mammographically occult breast carcinoma should be not considered as a 
contraindication to breast-conserving therapy at this point. 
 
BCT for Patients with Mammographically Occult Breast Cancer 
For patients who present with mammographically occult primary tumors 
(MamOcc) who opt for a breast conserving approach, it is unclear whether the 
presentation of MamOcc disease confers a worse outcome in terms of local control.  Data 
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on outcomes after BCT are limited, with some studies suggesting that patients with 
palpable disease and false-negative mammograms have a higher risk of diffuse or 
extensive disease and implying that these MamOcc patients may be poor candidates for 
BCT (32) while other studies suggest that MamOcc patients remain candidates for BCT 
(5, 6, 50).  Furthermore, issues regarding how to conduct long-term follow-up and detect 
future breast recurrences for patients initially undetected by mammography have evoked 
concern physicians and patients alike. 
In 1992, Samuels and colleagues published their experience with 542 patients 
with breast cancer treated with breast conserving therapy, of which 55 presented with 
MamOcc disease (5).   The local recurrence, 5-year actuarial survival, and 5-year disease-
free survival rates did not differ significant between the mammographically occult and 
mammographically evident cohorts (see Table 7).  The authors concluded that BCT is an 
appropriate treatment for patients with palpable but mammographically negative early 
stage breast cancer.  Similar conclusions were reached by Rajentheran et al. in their 
cohort of patients with 18-month follow up (50).  Finally, Morrow et al. found in their 
series of MamOcc cases that mammographically occult tumors were not associated with 
factors such as size, unfavorable histology, or multicentrity and therefore concluded that 
patients with mammographically negative early stage breast cancers are still candidates 
for BCT (6).    
The above studies suggest that BCT is suitable for patients with 
mammographically negative early stage breast cancer.  However, a histologic study of 
patients presenting with MamOcc disease by Hollingsworth et al. reported that a 
principal finding of patients presenting with false-negative mammograms is the diffuse 
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histology of the primary tumors (32). Voogd et al. reported in their series that 
mammographically occult breast cancers are associated with higher local recurrence rate 
after breast conserving therapy (7).  These studies indicate that BCT may be 
contraindicated in patients with mammographically occult tumors.   
 
Table 7: Local recurrence and survival of patients with mammographically occult 
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STATEMENT OF PURPOSE 
In this study, we examined our large institutional experience of early-stage breast 
cancer patients treated with BCT who initially presented with MamOcc disease, 
compared with patients who presented with positive mammograms (MamPos), to 
examine the clinical and pathologic features and long-term outcomes of these two groups 
of patients. Magnetic resonance imaging of the breast was not used in any of our patients 
as a method of detection in this study. In addition, we analyzed the recurrence patterns of 
these two cohorts of patients to determine the implications for follow-up for MamOcc 

















METHODS AND MATERIALS  
Patient Selection 
Between the years of 1974 and 2003, 214 MamOcc and 2168 MamPos patients 
with early-stage breast carcinoma underwent BCT at the Yale University School of 
Medicine, Department of Therapeutic Radiology. These two groups of patients 
constituted our study and reference cohorts, respectively, and were the focus of our study. 
After approval from the Human Investigations Committee was obtained, a chart review 
was conducted for assessment of mammogram reports and method of tumor detection for 
all available patients within our database, to confirm the MamOcc cohort. In addition, 
clinical parameters (method of tumor detection, age of diagnosis, family history), 
pathologic factors (T stage, nodal status, margin status, histology, expression of estrogen, 
progesterone, and HER-2 receptors) and outcomes (local–regional relapse, distant 
relapse, and overall survival) were recorded. Because of the era in which these patients 
were treated, the vast majority had axillary lymph node dissection. For those who did not 
have axillary lymph node dissection, axillary radiotherapy was delivered to treat the 
axillary contents. All patients received a median dose of 48 Gy to the whole breast, 
followed by a boost, for a median total dose of 64 Gy. Regional nodal radiation was 
delivered as clinically indicated and has been previously described (51-53).  Systemic 
therapy was delivered at the discretion of the treating physicians. All patients who were 
non-Caucasian were excluded from our outcomes analysis to ensure that race would not 
confound results, because the frequency of non-white vs. white patients was different for 
the MamOcc cohort (5.6% vs. 11.32%; p = 0.0354). Of the 2 cohorts, the white 




All clinical and pathologic features of the two cohorts were entered into a 
database and analyzed using SAS 9.1 (SAS Institute, Cary, NC). All tests of statistical 
significance were two-sided, and p values of <0.05 were considered statistically 
significant. Bivariate analyses for the association between covariables and 
MamOcc/MamPos were performed using χ2 and Fisher exact tests. The outcome 
parameters analyzed included breast relapse–free survival (defined as time from 
diagnosis to recurrent disease within the breast), distant recurrence–free survival (time of 
diagnosis to disease failure outside the local–regional area), cause-specific survival 
(interval from the date of diagnosis to the date of death from breast cancer or to the last 
follow-up date), and overall survival (interval between date of diagnosis and death). 
Comparison of clinical and pathologic characteristics between the MamOcc and MamPos 
groups was done using χ2 analysis. The outcome endpoints were calculated using 
standard life-table methods, and the differences were compared using Cox regression 
models. The outcome parameters were analyzed by multivariate analysis incorporating 
method of tumor detection, age at diagnosis, T stage, nodal status, margin status, HER-










Median follow-up was 8.4 years for MamOcc patients and 6.6 years for MamPos 
patients. The method of presentation for the 202 MamOcc patients was a palpable mass 
in all cases; there were no patients with T0 N+ (completely occult primary tumors 
presenting with lymph node involvement) in this analysis. The incidence of MamOcc 
over the study period in 4-year increments from 1975 to 2003 is shown in Fig. 1. The 
highest incidence occurred in the mid-1980s and then seems to have decreased over time. 
There were no significant differences in final margin status, T stage, or nodal status for 
the MamOcc vs. MamPos groups. The age at diagnosis differed significantly for the two 
cohorts; specifically, more patients in the MamOcc group presented at a young age (age 
≤40 years) than in the MamPos group (31% vs. 11%, p < 0.0001). The MamOcc group 
reported positive family history more often than patients in the MamPos cohort (46% vs. 
35%, p = 0.0033). Although all patients had invasive carcinoma, the primary histology of 
the tumor differed between the two cohorts, with the MamOcc patients having a higher 
incidence of infiltrating lobular carcinoma (12% vs. 5%) and a lower association with 
ductal carcinoma in situ (2% vs. 17%) when compared with the MamPos group (p < 
0.0001). Although the percentages of patients who were estrogen receptor positive, 
progesterone receptor positive, and triple negative (estrogen, progesterone, and HER-
2/neu negative) did not differ significantly between the two groups, the MamOcc patients 
were HER-2 positive less often (14% vs. 29%, p = 0.0294). Table 2 summarizes the 
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Abbreviations: MamOcc= mammographically occult cohort; MamPos= 
mammographically positive cohort; ILC= infiltrating lobular carcinoma; DCIS= ductal 
carcinoma in situ; ER= estrogen receptor; PR= progesterone receptor; HER-2= human 
epidermal growth factor receptor 2. 
 
Treatment parameters for the two cohorts were as follows: median dose to tumor 
bed was 64 Gy in both cohorts. All patients in the two cohorts underwent either axillary 
nodal dissection or radiation to the full axilla. There were differences in the percentages 
of patients who received chemotherapy (35% vs. 26%; p = 0.007) and adjuvant hormonal 
therapy (25% vs. 33%; p = 0.0135) for the MamOcc vs. MamPos cohorts, respectively. 
At 10 years there were no significant differences in survival outcomes between the two 
cohorts (overall survival, p = 0.693; cause-specific survival, p = 0.183). The distant 
metastasis rate between the two cohorts did not differ significantly (16% vs. 12%; p = 
0.586). 
Patients of the MamOcc cohort had a significantly higher breast relapse rate (15% 
vs. 8%; p = 0.036) compared with the MamPos patients and more nodal relapse (4% vs. 
1%; p = 0.008). The clinical outcomes of the MamOcc and MamPos cohorts at 10 years 
are detailed in Table 3, and the survival curves are shown in Fig. 2.  
 




MamOcc (%) MamPos (%) p value 
Breast Relapse Free Survival 
 
85 92 0.036 
Nodal Relapse Free Survival 
 
96 99 0.008 
Distant Disease Free Survival 
 
84 88 0.586 
Cause Specific Survival 
 




Abbreviations: abbreviations as in Table 7. 
 
When method of detection, age at diagnosis, T stage, nodal status, margin status, 
and HER-2 and triple-negative status were incorporated into the multivariate regression 
model, MamOcc disease was not an independent predictor of breast relapse–free survival 
(hazard ratio 1.0, 95% confidence interval 0.993–1.007, p = 0.9296) but remained an 
independent predictor of nodal relapse–free survival (hazard ratio 0.987, 95% confidence 
interval 0.975–1.000, p = 0.0483), as shown in Table 4 and Table 5.  
 
 




Variables Hazard ratio (95% CI) p value 
 
Mammography 
                      Positive 
                      Negative 
 
 
           1.0 (referent) 
           1.0 (0.993-1.007) 
0.9296 
Age 
                      < 40 
                      > 40 
 
 
           0.935 (0.494-1.768) 
           1.0 (referent) 
0.8359 
Tumor Size 
                      T1 







                      Negative 







                      Negative 

















                      Negative 




            0.953 (0.444-2.046) 
0.9014 
 
Abbreviations: HR= hazard ratio; CI= confidence interval; other abbreviations as in 
Table 7.   
 




Variables Hazard ratio (95% CI) p value 
 
Mammography 
                      Positive 
                      Negative 
 
 
           1.0 (referent) 
           0.987 (0.975-1.000) 
0.0483 
Age 
                      < 40 
                      > 40 
 
 
           2.677 (0.716-10.004) 
           1.0 (referent) 
0.1433 
Tumor Size 
                      T1 







                      Negative 







                      Negative 







                      Negative 







                      Negative 









Abbreviations: abbreviations as in Table 9 and Table 7.    
Of the MamOcc patients who sustained a breast recurrence, 32% (8 of 25) had a 
false-negative/mammographically occult tumor at the time of relapse. This contrasted 
with the MamPos patients, of whom only 13% (19 of 150) had false-
negative/mammographically occult tumors at local relapse. This difference in false-
negative mammograms at time of recurrence for the MamOcc and MamPos cohorts 




















Although mammography is the current standard method for breast imaging before 
definitive treatment for early-stage breast cancer, a fraction of patients will have primary 
tumors that are mammographically occult. The actual percentage of patients presenting 
with mammographically occult primary tumors at diagnosis has been stated to be as high 
as 35% in younger women (54) but generally is quoted to be in the range of 9–22% (1-4). 
Unfortunately, the long-term prognostic implications for early-stage breast cancer 
patients who present with mammographically occult tumors and who choose BCT is 
largely unknown. Most studies on MamOcc disease have focused on radiographic 
analysis, concentrating on retrospectively reviewing mammograms after the diagnosis of 
breast cancer to discern whether the primary tumor was initially missed. Although several 
smaller studies have attempted to address recurrence after BCT for MamOcc patients, to 
the best of our knowledge our study represents the largest series of MamOcc patients 
treated with conservative surgery and radiotherapy and characterizes differences in long-
term outcomes, as well as clinical and pathologic characteristics between MamOcc and 
MamPos patients. 
Several smaller studies have attempted to analyze clinical–pathologic 
characteristics, outcomes, and recurrence patterns in MamOcc patients after BCT. In 
1992, Samuels et al. (5) reported on outcomes and recurrences after BCT for MamOcc 
patients by analyzing 55 MamOcc and 487 MamPos patients who had undergone 
conservative surgery and radiotherapy. Consistent with our findings, they found that 
MamOcc patients presented at a younger age, with no difference in T stage and nodal 
status. They did not find any significant differences in local–regional control, distant 
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metastasis, or overall survival, and concluded that BCT is a suitable treatment option for 
MamOcc patients. Furthermore, in direct contrast to our findings, evaluation of 
mammograms at recurrence led them to conclude that “negative mammograms at the 
time of diagnosis are not predictive of a negative mammogram at recurrence.” It is 
possible that the differences in our findings are due to the significantly larger sample 
sizes of our two cohorts. Because our study had four times as many subjects as that of 
Samuels et al., we had greater statistical power to detect a difference. 
In 1999, Voogd et al. (7) took another approach to address the topic of BCT and 
MamOcc patients. They identified 39 patients who had local recurrence after BCT and 
126 randomly chosen patients without recurrence after conservative therapy, and 
reviewed all the reports from the initial and recurrence mammograms. They demonstrated 
that patients who presented initially with mammographically occult primary tumors had a 
higher risk of local recurrence after BCT, although the difference was only significant for 
patients aged <50 years. Again, the sample size for the MamOcc group was small (30 
patients), and there were only 4 patients in the cohort who were older than 50 years. They 
attempted to find an explanation for the association between mammographic findings and 
local recurrence by performing a central pathology review but did not find any factors 
that could potentially explain the increase in relapse for the MamOcc cohort. 
In a 2008 study, Weinstein et al. (55) characterized mammographic finding in 
patients who had undergone BCT and sustained a local relapse. Of their 26 patients who 
initially presented with MamOcc disease and developed a breast relapse, 23.1% had 
mammographically occult recurrences, which did not differ significantly from their 
cohort of recurrent patients who were initially MamPos. They concluded that “the 
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mammographic appearance of the original tumor does not always correlate with the 
recurrent tumor.” In contrast, Burrell et al. (56) retrospectively reviewed 31 patients with 
recurrent tumors and found a high concordance with the characteristics of the original 
mammogram. Because of the differences in design of these studies, neither of these 
publications spoke directly to the question of the characteristics of MamOcc patients who 
had undergone BCT but instead looked to characterize mammographic features of 
patients with recurrence. 
In the present study we found a younger age at presentation, more invasive 
lobular histology, and less association with ductal carcinoma in situ in our MamOcc 
cohort, consistent with findings in other studies (2, 6, 31, 57).  We also found a 
significant difference in the incidence of self-reported positive family history between 
our MamOcc and MamPos cohort, and less HER-2/neu–positive disease. It is notable that 
we did not find a difference in primary T stage of the tumor (i.e. T1 vs. T2 disease) or 
more nodal involvement in the MamOcc cohort. 
In addition, the negative margin rate between the two cohorts was comparable, a 
finding of particular importance because mammography has been the standard tool used 
by surgeons to delineate the location and extent of disease to determine whether a patient 
will be a candidate for successful breast-conserving surgery. In our series, the percentage 
of patients with positive margins in both cohorts was exactly equal, which suggests that 
false-negative mammograms at presentation are not a predictor for positive margins (or 
inability to completely excise the primary tumor). It is important to note that our two 
cohorts were treated over a span of nearly 3 decades, in an era in which MRI of the breast 
was not available for routine use at our institution. Our mammographically occult cohort 
30 
 
generally went directly to biopsy (with or without ultrasound). With the frequent use of 
MRI in our current practices, contemporary workup for a MamOcc patient seen in our 
clinics today would likely result in positive MRI findings. Furthermore, with the current 
widespread use of breast MRI, it is even more unlikely that there would be any 
differences in outcomes for patients treated today. 
We did note that the delivery of systemic therapy differed for the MamOcc and 
the MamPos cohorts. The MamOcc patients received more chemotherapy, and the 
MamPos patients received more adjuvant hormone therapy. This is likely explained by 
the fact that the MamOcc patients were younger and were therefore given chemotherapy 
more frequently and received hormones less frequently, although we did not find a 
difference in the estrogen/progesterone receptor status of the two study cohorts. Our 
outcomes analysis suggests there is no difference in distant disease–free survival, cause-
specific survival, or overall survival between the two cohorts at 10 years. Although the 
differences we noted in breast relapse–free survival were statistically significant on 
univariate analysis, mammographically occult primary tumors at diagnosis were not an 
independent predictor of local relapse on multivariate analysis when taking into account 
the other confounding factors. MamOcc disease remained an independent predictor of 
nodal recurrence on multivariate analysis, but because the numbers of nodal relapses 
overall were very small, no firm conclusions can be drawn from these data as to the cause 
of increased nodal relapses in MamOcc patients. 
An important finding of our study is the lower mammographic detectability of the 
recurrent cancers in the MamOcc cohort after BCT. These results lead us to conclude that 
clinical and pathologic differences in the MamOcc and MamPos patients ultimately result 
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in more false-negative mammograms at recurrence for the MamOcc cohort, suggesting 
that this population of patients should be considered for closer clinical follow-up and 
alternative imaging strategies, such as ultrasound and breast MRI after BCT. 
There are several limitations to our study that warrant further discussion. Intrinsic to the 
nature of all retrospective studies, selection biases cannot be entirely accounted for. 
Furthermore, although the number of patients in our cohorts was relatively large, it is 
possible that the differences in outcomes did not achieve statistical significance owing to 
the study being underpowered. Most importantly, although a review of all mammogram 
reports was conducted to verify the MamOcc cohort, we did not conduct a central review 
of the actual mammograms to determine what percentage of these mammographically 
occult tumors were due to “radiological oversight.” In addition, the use of other imaging 
modalities (i.e., breast ultrasound) was not evaluated in this study. 
Finally, our study is based on a single-institution experience, and multi-
institutional evaluation of larger patient population is needed to eliminate biases based on 
differences that may exist in patient demographics, diagnostic procedures, and 
therapeutic interventions from one institution to the next. 
In conclusion, our series suggests that there are clinical–pathologic differences in 
MamOcc vs. MamPos patients that may ultimately affect management and outcomes. 
MamOcc patients present at a younger age, have invasive lobular histology more often, 
are less often associated with ductal carcinoma in situ, and have less HER-2/neu–positive 
disease. Although local control does not seem to be compromised in MamOcc patients 
undergoing BCT, these patients have a higher tendency to have false-negative 
mammograms at the time of breast recurrence and therefore should be considered for 
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closer clinical follow-up and alternative imaging strategies, such as ultrasound and breast 
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Fig. 1. Incidence of mammographically occult (MamOcc) patients over the study period 





Fig. 2. Ten-year clinical outcomes of mammographically occult (red) and 
mammographically positive (black) cohorts. (a) Breast relapse–free survival; (b) nodal 
relapse–free survival; (c) disease-free survival; (d) cause-specific survival; (e) overall 
survival. 
 
